A Phase 3 interventional study of Dexamethasone and Backrest elevation in Out-Of-Hospital Cardiac Arrest and Post-Cardiac Arrest Syndrome, sponsored by Christian Hassager. Active, not recruiting at 5 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Christian Hassager · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark — 7 open to participants now, 8 under way, 2 of them phase 3. Out-of-Hospital Cardiac Arrest · Denmark.
Among the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, this one is the 9th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 33rd registered.
314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.
Browse Out-of-Hospital Cardiac Arrest studies →7 of the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark are open now. Recruiting first, the newest first:
Lars Wiuff Andersen · Sites in Denmark
Ages 18+
Christian Hassager · Sites in Denmark
Ages 18+
Emergency Medical Services, Capital Region, Denmark · Sites in Denmark
Ages 8+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Bo Gregers Winkel · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.
Median enrollment 376 across the 26 interventional studies, 900 across the 12 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 38 have an industry lead sponsor. The 10 most frequent:
Christian Hassager is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Christian Hassager has 4 studies filed under Out-of-Hospital Cardiac Arrest — fewer than ten, so there is no comparison to draw.
3 of the studies in Out-of-Hospital Cardiac Arrest with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05895838Phase 3Christian HassagerThe Danish Out-of-Hospital Cardiac Arrest Study | 2027-09 |
| NCT04446585Emergency Medical Services, Capital Region, DenmarkCardiac Arrest in Residential Areas With Mobile First-responder Activation | 2027-01 |
| NCT06744361Christian HassagerKetamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
After resuscitation from Out-of-Hospital Cardiac Arrest (OHCA) patients experience Post Cardiac Arrest Syndrome due to ischemia and reperfusion injury. It consists of systemic inflammation, cerebral and myocardial dysfunction, and the condition that led to the arrest. Most OHCA patients will receive critical care intubated in an Intensive Care Unit (ICU). Despite this \~50% die; mainly due to brain injury. Several targets can be considered for improving outcomes. To dampen systemic inflammation and optimize cerebral perfusion seem important. Deep sedation has been required for targeted temperature management (TTM) but may also be brain protective. After end of sedation, many patients have some cerebral dysfunction that may facilitate delirium.
The aim of this trial is therefore to improve treatment of comatose OHCA patients by evaluating 4 interventions in a factorial design addressing each of these targets in a randomized clinical trial:
The trial is designed as a phase III trial, randomizing 1000 patients at Danish cardiac arrest centers.
The primary endpoint is 90 days all-cause mortality for the interventions targeting systemic inflammation and cerebral perfusion, while it is days alive outside of hospital within 30 days for the interventions concerning duration of sedation and delirium.
The trial has potential to improve outcomes for comatose OHCA patients - a group with a grave prognosis with currently only limited evidence-based treatments.
BACKGROUND
Initially resuscitated Out-of-Hospital Cardiac Arrest (OHCA) patients admitted to a hospital are often in an unstable condition necessitating both circulatory and respiratory support. Most of these patients experiences the Post Cardiac Arrest Syndrome (PCAS) immediately after resuscitation due to a whole-body ischemia and reperfusion injury. It consists of four elements: 1) a universal systemic inflammatory response, 2) cerebral dysfunction, 3) myocardial dysfunction, and 4) the precipitation condition that led to the cardiac arrest - often a coronary occlusion.
The majority of OHCA patients have a presumed cardiac cause for their cardiac arrest. These patients are all evaluated for immediate coronary revascularization, stabilized with vasopressors, inotropes or mechanical circulatory support, and if comatose further sedated, connected to a ventilator and given targeted temperature management (TTM) for at least 24 hours. Half of the admitted resuscitated OHCA patients still die during the hospitalization despite all these interventions. The main cause of death is withdrawal of life sustaining therapy due to irreversible brain injury.
Several targets can be approached in order to potentially improve the outcome of OHCA patients. During the initial phase early after hospital admittance, interventions to dampen the systemic inflammatory response and efforts to secure optimum cerebral perfusion pressure seem intuitive important. Deep sedation has been required for TTM but may also have brain protective effects. After discontinuation of the sedation when the TTM is over, most patients have some degree of cerebral dysfunction. This may make them more prone to develop delirium in the days after awakening which is an independent risk factor in critical ill patients.
The DANOHCA trial will therefore evaluate new potential interventions to each of these different targets: systemic inflammation, cerebral perfusion, duration of sedation, and delirium.
INTERVENTIONS
High-dose steroids to dampen systemic inflammation in resuscitated OHCA patients:
By randomization, the patients will be allocated 1:1 to either dexamethasone (administered as dexamethasonephosphate) or placebo for three days. As soon as possible after admittance 20 mg of dexamethasonephosphate (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo will be given intravenously (i.v.) over 15 minutes - followed by 20 mg dexamethasonephosphate (or placebo) i.v. administered daily at 0600 (or at least 8 hours after initial dose) for two days, for a total of 3 doses.
Backrest elevation in post cardiac arrest care and outcome for OHCA patients:
By randomization, the patients will be allocated to have their headrest positioned at 5 degrees backrest vs 35 degrees straight elevation of backrest in Semi-Fowler's position (elevated lower limp position) during the initial 72 hours or until extubated. The adherence to the assigned stratum will be checked every 8 hours and cuff pressure will be assessed and corrected if needed at the same time during the intervention period. The backrest position intervention may be temporarily canceled by the treating physician if needed for procedures or mobilization but will return to the assigned position if invasive ventilator treatment with orotracheal intubation is continued. The intervention will be terminated if the patient is extubated, or a tracheostomy is performed, during the intervention period of 72 hours.
Early wake up and extubation in OHCA patients:
By randomization, the patients will be allocated 1:1 to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU. Definition for "ready for extubation" will be: GCS≥12, RASS 0 to -1, able to raise arm or voluntary hand shake on command, spontaneous breathing trial and low ventilator settings (pressure support≤14, PEEP≤8 (10 if obese), and FiO2≤40%). A wakeup call may for both groups be aborted for the following reasons: seizures, respiratory distress, shock, or "other cause" with specification. Sedation prior to the scheduled wakeup calls is permitted in the early wakeup call group as needed for clinical care, while it is mandatory for the late wakeup call group. For both groups, sedation as needed for clinical care will be permitted after the scheduled wakeup call.
Prophylactic use of olanzapine to prevent delirium in patients resuscitated from OHCA:
By randomization, the patients will be allocated 1:1 to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses. As soon as possible after arriving at the ICU: olanzapine/placebo is given by feeding tube. Thereafter 10 mg olanzapine or matching placebo will be given by feeding tube (or orally in awake patients) the following two evenings at 1800 (with a minimum of 12 hours between the initial doses) for a total of 3 doses. Due to the potential QT-prolonging effect, and accompanying concern for arrythmia, patients will be excluded prior to randomization if Long QT Syndrome (LQTS) has been confirmed or suspected, and all patients will be monitored by mandatory telemetry of heart rhythm for 96 hours or until life sustaining therapies are withdrawn. In case of delirium, patients are treated according to standard care most often including dexmedetomidine, haloperidol or midazolam.
STUDY DESIGN
The study is an investigator-initiated, randomized, controlled, multicenter clinical trial with co-enrollment into 4 different interventions. The pharmacological interventions are placebo-controlled, double-blind interventions and physiological interventions of early wakeup and extubation, as well as the back-rest position interventions are open label. Following successful completion of screening procedures, patients will be randomized in a 1:1 fashion to receive either the active intervention or placebo/control intervention for each intervention. The randomization will be revealed by opening a sealed box (referred to as the "DANOHCA trial kit" below) containing the study drug vials/tablets, instructions for wakeup and extubation and backrest positioning.
The trial aims to include 1000 patients from 5 sites. Approximately 350 patients are eligible for inclusion at the five hospitals combined each year, and therefore inclusion is expected to be concluded after 3-4 years.
Sub-studies further investigating the effect of the interventions will be performed. A research biobank will be established. Further co-enrollment into additional trials must be permitted by the steering group after careful assessment of risk of interaction with the four per-protocol interventions.
STATISTICAL ANALYSES
The data will be analyzed and reported as 4 individual trials, hence no adjustment for multiple comparison is planned.
Should more than one of the interventions be non-neutral a post hoc evaluation of interaction will be performed and highlighted in the reporting of the results. Also, as an investigation of potential safety aspects related to possible interactions between the four interventions, interactions related to mortality and occurrence of other SAE' will be reported.
All analyses will be conducted in the modified intention-to-treat (ITT) population with a set two-level significance level of 0.05. Modified ITT in this regard means that patients included without fulfilling the inclusion criteria will be excluded from the analyses.
Throughout, categorical variables will be presented as numbers (frequencies), whereas continuous variables will be presented as mean ±SD if normally distributed, and as median (25th percentile-75th percentile) if non-normally distributed. The primary analysis of primary endpoint will include the modified ITT population. Further the investigators plan a sensitivity analysis in the per protocol population to assess the effect. The per protocol cohort will be defined as only those trial participants who have received ALL scheduled doses of the pharmacologic interventions, have adhered to the assigned back-rest position for ≥80% of the time, and have had a wake-up call attempted within the assigned time frames.
Continuous endpoints being assessed at multiple time points will be analyzed by application of linear mixed models of covariance. The main result of these analyses will be the treatment-by-time interaction as a marker of whether the individual endpoint changes differently over time in the active intervention vs. the placebo arm, and group differences will be reported as relative differences in %. Logarithmic transformation will be applied to approximate normal distribution as appropriate.
Categorical endpoints by treatment allocation will be analyzed by the Chi-Squared or the Fisher's exact test, as appropriate.
For analysis of survival data, Kaplan-Meier curves for each allocation group will be estimated, graphically displayed, and compared by the log-rank test. Further Cox proportional hazard models will be applied to assess differences in time to death between treatment groups. These models will sequentially be adjusted for the interaction between treatment allocation, and each of the following variables: sex, age, time to ROSC, lactate level upon admission, shockable primary rhythm, witnessed cardiac arrest, bystander performed cardiopulmonary resuscitation, presence of STEMI in the admission ECG. Further, models stratified by cause of death (cardiovascular, neurological, multi-organ failure) will be applied as hypothesis generating. Any changes from the pre-specified analysis plan will be reported.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
As soon as possible after hospital admittance 20 mg of dexamethasonephosphate (Dexavit, Vital Pharma Nordic ApS, Denmark) will be given intravenously (i.v.) over 15 minutes - followed by 20 mg dexamethasonephosphate (or placebo) i.v. administered daily at 0600 (or at least 8 hours after initial dose) for two days, for a total of 3 doses. For this arm the dexamethasonephosphate solution is provided in the "DANOHCA trial kit" in the form of Dexavit at a concentration of 4mg/mL stored in glass vials of 5mL; three vials are provided in total.
Drug: Dexamethasone
As soon as possible after hospital admittance placebo (isotonic saline) will be given intravenously (i.v.) over 15 minutes - followed by placebo solution administered i.v. daily at 0600 (or at least 8 hours after initial dose) for two days, for a total of 3 doses. For this arm the placebo solution is provided in the "DANOHCA trial kit" in the form of isotonic sodium chloride stored in glass vials of 5mL; three vials are provided in total.
Drug: Dexamethasone
As soon as possible after hospital admittance the patients will have their headrest positioned at 35 degrees straight elevation of backrest in Semi-Fowler's position (elevated lower limp position). This position will be maintained during the initial 72 hours or until extubated. Adherence to assigned stratum will be checked every 8 hours and cuff pressure will be assessed and corrected if needed at the same time during the intervention period. The backrest position intervention may be temporarily canceled by the treating physician if needed for procedures or mobilization but will return to the assigned position if invasive ventilator treatment with orotracheal intubation is continued. The intervention will be terminated if the patient is extubated, or a tracheostomy is performed, during the intervention period of 72 hours.
Procedure: Backrest elevation
As soon as possible after hospital admittance the patients will have their headrest positioned at 5 degrees straight elevation of backrest in Semi-Fowler's position. This position will be maintained during the initial 72 hours or until extubated. Adherence to assigned stratum will be checked every 8 hours and cuff pressure will be assessed and corrected if needed at the same time during the intervention period. The backrest position intervention may be temporarily canceled by the treating physician if needed for procedures or mobilization but will return to the assigned position if invasive ventilator treatment with orotracheal intubation is continued. The intervention will be terminated if the patient is extubated, or a tracheostomy is performed, during the intervention period of 72 hours.
Procedure: Backrest elevation
Patients will be subjected to a wakeup call and potential extubation after ≤6 hours after admission to the ICU. Definition for "ready for extubation" will be: GCS≥12, RASS 0- -1, able to raise arm or voluntary hand shake on command, spontaneous breathing trial and low ventilator settings (pressure support≤14, PEEP≤8 (10 if obese), and FiO2≤40%). A wakeup call may be aborted for the following reasons: seizures, respiratory distress, shock, or "other cause" with specification. Sedation prior to the scheduled wakeup calls is permitted in this early wakeup call group as needed for clinical care, while it is mandatory for the late wakeup call group. For both groups sedation as needed for clinical care will be permitted after the scheduled wakeup calls. For this arm, information on the assigned time for wakeup call is provided in the "DANOHCA trial kit". The assigned time for wakeup will be noted in the electronic patient file.
Procedure: Early wakeup call
Patients will be subjected to a wakeup call and potential extubation after 28-36 hours after admission to the ICU. Definition for "ready for extubation" will be: GCS≥12, RASS 0- -1, able to raise arm or voluntary hand shake on command, spontaneous breathing trial and low ventilator settings (pressure support≤14, PEEP≤8 (10 if obese), and FiO2≤40%). A wakeup call may be aborted for the following reasons: seizures, respiratory distress, shock, or "other cause" with specification. Sedation prior to the scheduled wakeup calls is mandatory for this late wakeup call group. For both groups sedation as needed for clinical care will be permitted after the scheduled wakeup calls. For this arm, information on the assigned time for wakeup call is provided in the "DANOHCA trial kit". The assigned time for wakeup will be noted in the electronic patient file.
Procedure: Early wakeup call
As soon as possible after arriving at the ICU olanzapine 10mg (dissolved tablet) is administered by feeding tube. Thereafter 10 mg olanzapine is administered by feeding tube (or orally in awake patients) the following two evenings at 1800 (with a minimum of 12 hours between the initial doses) for a total of 3 doses. Due to the potential QT-prolonging effect, and concern for arrythmia, patients will be excluded prior to randomization if Long QT Syndrome (LQTS) is suspected, and telemetry of heart rhythm is mandatory for 96 hours or until life sustaining therapies are withdrawn. In case of delirium patients are treated according to standard care most often including dexmedetomidine, haloperidol or midazolam. For this arm the olanzapine tablets are provided in the "DANOHCA trial kit" in the form of olanzapin 10mg tablets (Accord Healthcare B.V., The Netherlands); three tablets are provided in total. Prior to administration by feeding tube the tablets are dissolved in water.
Drug: Olanzapine
As soon as possible after arriving at the ICU a placebo tablet (dissolved) is administered by feeding tube. Thereafter placebo will be administered by feeding tube (or orally in awake patients) the following two evenings at 1800 (with a minimum of 12 hours between the initial doses) for a total of 3 doses. Due to the potential QT-prolonging effect of olanzapine, and accompanying concern for arrythmia, patients will be excluded prior to randomization if LQTS is suspected, and telemetry of heart rhythm is mandatory for 96 hours or until life sustaining therapies are withdrawn. In case of delirium patients are treated according to standard care most often including dexmedetomidine, haloperidol or midazolam. For this arm the placebo tablets are provided in the "DANOHCA trial kit" in the form of placebo tablets manufactured by the Pharmacy of the Capital Region; three tablets are provided in total. Prior to administration by feeding tube the tablets are dissolved in water.
Drug: Olanzapine
Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.
Also known as: Dexavit
Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).
Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.
Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
Steroid intervention primary endpoint: All-cause mortality
Number of patients dying from all causes
Time frame: 90 days
Back rest position intervention primary endpoint: All-cause mortality
Number of patients dying from all causes
Time frame: 90 days
Early wakeup and extubation intervention primary endpoint: Days alive outside hospital
Counted as days alive outside of hospital after discharge
Time frame: 30 days
Olanzapine intervention primary endpoint: Days alive outside hospital
Counted as days alive outside of hospital after discharge
Time frame: 30 days
Steroid intervention: Number of patients with one or more serious adverse reactions to dexamethasone in the ICU
Number of patients with one or more serious adverse reactions to dexamethasone in the ICU
Time frame: Patients will be monitored for the occurrence of an adverse event for 30 days after randomization or until hospital discharge if this occurs later than 30 days and will not be followed for adverse event reporting after this.
Steroid intervention: Days alive outside hospital within 30 days
Days alive outside hospital within 30 days
Time frame: 30 days
Steroid intervention: Cerebral Performance Category (CPC) and Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest
Cerebral Performance Category (CPC) and Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest (conducted either through physical attendance or telephone interview according to participant preference)
Time frame: 3-6 months
Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest
Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest (conducted either through physical attendance or telephone interview according to participant preference)
Time frame: 3-6 months
Steorid intervention: Serum Neuron Specific Enolase (NSE) at 48-72 hours
Serum Neuron Specific Enolase (NSE) at 48-72 hours
Time frame: 48-72 hours
Steroid intervention: Markers of inflammation (high-sensitivity C reactive protein)
Markers of inflammation; high-sensitivity C reactive protein. platelet-, leukocyte- and differential count daily during the initial 72 hours
Time frame: 0-72 hours
Steroid intervention: Markers of inflammation (platelet count)
Markers of inflammation; high-sensitivity C reactive protein. platelet-, leukocyte- and differential count daily during the initial 72 hours
Time frame: 0-72 hours
Steroid intervention: Markers of inflammation (leukocyte- and differential count)
Markers of inflammation; high-sensitivity C reactive protein. platelet-, leukocyte- and differential count daily during the initial 72 hours
Time frame: 0-72 hours
Backrest position intervention: Serum Neuron Specific Enolase (NSE) at 48 hours at sites where this is in routine use.
Serum Neuron Specific Enolase (NSE) at 48 hours at sites where this is in routine use.
Time frame: 48 hours
Backrest position intervention: Duration of intubation (oral and tracheostomy combined)
Duration of intubation (oral and tracheostomy combined)
Time frame: During the index hospital admission, assessed up to 1 year after randomization
Backrest position intervention: ICU length of stay
ICU length of stay
Time frame: During the index hospital admission, assessed up to 1 year after randomization
Backrest position intervention: Days alive outside hospital within 30 days
Days alive outside hospital within 30 days
Time frame: 30 days
Backrest position intervention: Hospital length of stay
Backrest position intervention: Hospital length of stay (including in-patient rehabilitation and transfer to referral hospital)
Time frame: During the index hospital admission, assessed up to 1 year after randomization.
Backrest position intervention: Cerebral Performance Category (CPC) at 3-6 months follow-up.
Cerebral Performance Category (CPC) and the modified Rankin Scale (mRS) at 3-6 months follow-up (conducted either through physical attendance or telephone interview according to participant preference).
Time frame: 3-6 months
Backrest position intervention: The modified Rankin Scale (mRS) at 3-6 months follow-up.
Cerebral Performance Category (CPC) and the modified Rankin Scale (mRS) at 3-6 months follow-up (conducted either through physical attendance or telephone interview according to participant preference).
Time frame: 3-6 months
Early wakeup and extubation intervention: All-cause mortality at 90 days.
All-cause mortality at 90 days
Time frame: 90 days
Early wakeup and extubation intervention: Cerebral Performance Category (CPC) at 3-6 months.
Cerebral Performance Category (CPC) and the modified Rankin Scale (mRS) at 3-6 months. CPC and mRS scores are collected during routine trial follow-up, conducted either through physical attendance or telephone interview according to participant preference. In either case, patients are asked to complete a questionnaire in advance.
Time frame: 3-6 months
Early wakeup and extubation intervention: The modified Rankin Scale (mRS) at 3-6 months.
Cerebral Performance Category (CPC) and the modified Rankin Scale (mRS) at 3-6 months. CPC and mRS scores are collected during routine trial follow-up, conducted either through physical attendance or telephone interview according to participant preference. In either case, patients are asked to complete a questionnaire in advance.
Time frame: 3-6 months
Early wakeup and extubation intervention: Duration of mechanical ventilation.
Duration of mechanical ventilation.
Time frame: During the index hospital admission, assessed up to 1 year after randomization
Early wakeup and extubation intervention: ICU length of stay.
ICU length of stay.
Time frame: During the index hospital admission, assessed up to 1 year after randomization
Early wakeup and extubation intervention: Hospital length of stay.
Hospital length of stay.
Time frame: During the index hospital admission, assessed up to 1 year after randomization
Olanzapine intervention: All-cause mortality at 90 days
All-cause mortality at 90 days
Time frame: 90 days
Olanzapine intervention: Number of CAM-ICU negative days at 30 days
Number of CAM-ICU negative days at 30 days
Time frame: 30 days
Olanzapine intervention: Number of days without pharmacological treatment for delirium
Number of days without pharmacological treatment for delirium (other than study drug during the intervention period)
Time frame: 72 timer
Olanzapine intervention: Cerebral Performance Category (CPC) at follow-up 3-6 months after cardiac arrest
Cerebral Performance Category (CPC) and Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest
Time frame: 3-6 months
Olanzapine intervention: The Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest
Cerebral Performance Category (CPC) and Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest
Time frame: 3-6 months
Olanzapine intervention: Number of patients with one or more serious adverse reactions to olanzapine in the ICU
Number of patients with one or more serious adverse reactions to olanzapine in the ICU
Time frame: Patients will be monitored for the occurrence of an adverse event for 30 days after randomization or until hospital discharge if this occurs later than 30 days and will not be followed for adverse event reporting after this.
Plan to share: No
Started Jun 2023 (actual). Primary completion is estimated for Sep 2027, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Olanzapine
Out-of-Hospital Cardiac Arrest →
Christian Hassager